9
Feb
2026
Hike the High Sierras in August 2026 for Damon Runyon Cancer Research
Today I’m hiking on the highest mountain in Africa with 20 people who care deeply about alleviating suffering from cancer. Together, we’ve raised $1.2 million for cancer research. These resources will launch the careers of three young scientists in the US. We are forming deep, meaningful friendships on the trail. We are savoring the grandeur of Mother Nature, and the... Read More
9
Feb
2026
Gear Check: Timmerman Traverse for Damon Runyon Heads to Kilimanjaro
Gear check is when it starts getting fun and getting real. Our team of 21 hikers has arrived in Tanzania and gotten all our gear sorted. We’ll start the trek on Kilimanjaro Feb. 10. Then we spend the next seven days together on the trails to the top of the highest peak in Africa, elevation 19,341 feet / 5,895 meters.... Read More
8
Feb
2026
Can We Ride the GenAI Wave Without Getting Subsumed by It?
“There are decades where nothing happens; and there are weeks where decades happen,” said Lenin, probably never. It’s also a remarkably apt characterization of the last year in generative AI (genAI) — the last week in particular — which has seen the AI landscape shift so dramatically that even skeptics are now updating their priors in a more bullish direction.... Read More
5
Feb
2026
Eikon Goes Public, Generate Biomedicines Teed Up, & Sante Reloads
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Feb
2026
The Problem with Platform Companies
I should start by saying that I am currently the CEO of a platform company. (We’re not talking publicly about what we’re doing yet.) Yes, I recognize the contradiction between the headline of this piece and my own career choice. No, I don’t like calling it a platform company—even if that’s what it is. There are a few different species... Read More
29
Jan
2026
Eikon IPO on Deck, Biomarin Borrows Big, & Halozyme Rolls with the Surf
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Jan
2026
Time Traps That Slow Down Small Teams
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jan
2026
Science and Industry Need to Push Back Hard
The days of strongly worded letters, statements to the press, white papers, and op-eds are over. The people dismantling science are coming at all we care about with a pliers and a blowtorch. If I have learned anything in the past year as founder of Stand Up for Science, it is that most of the people who value science and... Read More
22
Jan
2026
GSK Scoops Up RAPT, Genentech Bets on NC, & Relief for American Science
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2026
Helping People Lose Weight and Live Healthy: Ron Renaud on The Long Run
Ron Renaud is today’s guest on The Long Run. He is the CEO of Waltham, Mass.-based Kailera Therapeutics. Kailera is pursuing what could be the biggest opportunity in pharmaceutical industry history. It’s developing a portfolio of GLP-1-based drugs for obesity. Drugs in this category have been around a long time for treatment of Type 2 diabetes, but over the last... Read More
15
Jan
2026
Novo Rolls Out Wegovy Pill, Lilly Acquires Ventyx NLRP3, and Aktis Breaks IPO Ice
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Jan
2026
Sovereign Risk: The Geopolitical Price of Outsourcing the Biotech Engine
On the surface, delegates at this year’s JP Morgan Healthcare Conference have reason to be pleased. The Nasdaq Biotech Index was up 30% last year. After years of public market woes, it looks like there is light at the end of the tunnel. Some structural issues still exist – 10 years to get a molecule to clinic, regulators that need... Read More
8
Jan
2026
Following the Science to Immunology: Kate Haviland on The Long Run
Kate Haviland is today’s guest on The Long Run. Kate is the former CEO of Cambridge, Mass.-based Blueprint Medicines. Blueprint was one of the big biotech success stories of 2025. The company was acquired by Sanofi for $9.1 billion in cash at closing, and potentially $9.5 billion if certain milestones are met. The company started out with a vision for... Read More
7
Jan
2026
Biotech Needs Its Own David Sacks
One question from 2025 has consistently frustrated me: Why did AI and crypto become top strategic priorities in the first year of the Trump Administration while biotech was largely ignored? Trump’s core issues over the last decade have been immigration, trade, energy dominance, border security, China, and re-shoring of US manufacturing. It was not obvious that “Artificial Intelligence” and “digital... Read More
6
Jan
2026
Timmerman Traverse for Damon Runyon Hits $1M Goal, Striving Toward Kilimanjaro
The Timmerman Traverse for Damon Runyon Cancer Research Foundation has done it again. We have exceeded our team goal of raising $1 million for brilliant young cancer researchers around the US. We currently stand at $1,094,672. This team isn’t done. The latest group of 22 biotech executives and investors have one month left before traveling to Tanzania, banding together in common... Read More
6
Jan
2026
Variant Bio Attracts Boehringer With AI Discovery of Kidney Disease Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Dec
2025
The Next Alzheimer’s Treatments May Spur the Brain to Protect Itself
The Alzheimer’s research community has tried for decades to get rid of amyloid plaques in the brain, in hopes of slowing down or preventing the memory-robbing disease. But amyloid might not be an insurmountable enemy after all. A remarkable group of people whose ability to resist the cognitive decline of Alzheimer’s was, until recently, completely invisible. These were individuals who... Read More
18
Dec
2025
Lilly Rolling in Obesity, Kymera Challenges Dupixent & Takeda Nails Tyk2
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Dec
2025
Small Molecules to Correct a Rare Kidney Disease: Emily Conley on The Long Run
Emily Conley is today’s guest on The Long Run. She is the CEO of Berkeley, Calif.-based Renasant Bio. The big idea at Renasant is to develop oral small molecule drugs to treat patients with autosomal dominant polycystic kidney disease, known as ADPKD. Patients with this disease develop cysts on their kidneys that sometimes cause the kidney to balloon in size... Read More
15
Dec
2025
Biotech’s Future Will Be More Distributed
When we started our first biotech company, MediChem Life Sciences in the early 1990s in Chicago, there was nothing resembling a “biotech ecosystem” nearby. We had to build our own labs, figure out how to raise money and how to recruit a team of scientists and professionals. The universities in the Chicago area were more focused on basic science. The... Read More